Describe impacto de la enfermedad tromboembolica en el perioperatoria, estudios de los nuevos anticoagulantes usados en profilaxis y sesgos de los estudios que apoyan su uso
It describes the impact of perioperative thromboembolic disease, evidence of the studies for prophylaxis and probable biases
15. rápido inicio de acción
administración oral
actuan específicamente sobre una enzima
excreción renal:
apixaban 25%
rivaroxaban 66%
dabigatran 80%
interacción con drogas y alimentos
53. No inferioridad
• Objetivo: demostrar que un tratamiento experimental “no es
peor” que un control activo
2 principios
• No se le puede negar a un paciente un tratamiento
reconocidamente efectivo
• el grado de rigor científico es suficiente para evitar
tratamientos inefectivos o inferiores
54. > probabilidad de sesgo
selección inapropiada de pacientes
pobre adherencia al tratamiento
mediciones de resultados no discriminatorias
inconsistencia entre observadores
seguimiento muy corto
gran cantidad de datos no recolectados
55. Análisis ITT vs. por protocolo
• Ambos con gran probabilidad de sesgo
• ITT: Favorece probabilidad de error tipo I
• PP: Excluye datos de pacientes que violan protocolo
• Deben realizarse los 2 análisis y se considera positivo si
ambas estrategias apoyan la no inferioridad
81. 1. Prevention of venous thromboembolism: American
College of Chest Physicians Evidence-Based Clinical
Practice Guidelines(8th Edition). Chest. 2008; 133(6
Suppl):381S-453S.
2. Prevention of VTE in Orthopedic Surgery Patients
Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice
Guidelines CHEST 2012; 141(2)(Suppl): e278S–
e325S
3. Dabigatran etexilate versus enoxaparin for
prevention of venous thromboembolism after total hip
replacement: a randomised, doubleblind, non-
inferiority trial. Lancet. 2007; 370(9591):949-956.
4. Rivaroxaban versus enoxaparin for
thromboprophylaxis after hip arthroplasty. N Engl J
Med. 2008; 358(26):2765-2775.
5. Extended duration rivaroxaban versus short term
enoxaparin for the prevention of venous
thromboembolism after total hip arthroplasty: a
double-blind, randomised controlled trial. Lancet.
2008; 372(9632):31-39.
6. Apixaban versus enoxaparin for thromboprophylaxis
after hip replacement. N Engl J Med. 2010; 363(26):
2487-2498.
7. Oral dabigatran versus enoxaparin for
thromboprophylaxis after primary total hip
arthroplasty (RE-NOVATE II*). A randomised, double-
blind, non-inferiority trial. Thromb Haemost. 2011;
105(4):721-729.
8. Oral dabigatran etexilate vs. subcutaneous
enoxaparin for the prevention of venous
thromboembolism after total knee replacement: the
RE-MODEL randomized trial. J Thromb Haemost.
2007; 5(11):2178-2185.
9. Oral thrombin inhibitor dabigatran etexilate vs North
American enoxaparin regimen for prevention of
venous thromboembolism after knee arthroplasty
surgery. J Arthroplasty. 2009; 24(1):1-9.
10.Rivaroxaban versus enoxaparin for
thromboprophylaxis after total knee arthroplasty. N
Engl J Med. 2008; 358(26):2776-2786.
11.Apixaban or enoxaparin for thromboprophylaxis after
knee replacement. N Engl J Med. 2009; 361(6):
594-604.
12.Apixaban versus enoxaparin for thromboprophylaxis
after knee replacement (ADVANCE-2): a randomised
double-blind trial. Lancet. 2010; 375(9717):807-815.
13.Rivaroxaban versus enoxaparin for
thromboprophylaxis after total knee arthroplasty
(RECORD4): a randomised trial. Lancet. 2009;
373(9676):1673-1680.
14.Dabigatran, Rivaroxaban and Apixaban versus
Enoxaparin for thomboprophylaxis after total knee or
hip arthroplasty: Pool-analysis of phase III
randomized clinical trials.Thrombosis Research 130;
(2012):183–191
15.The new oral anticoagulants. Blood. 2010; 115(1):
15-20.
16.The pharmacokinetics, pharmacodynamics and
tolerability of dabigatran etexilate, a new oral direct
thrombin inhibitor, in healthy male subjects. Br J Clin
Pharmacol. 2007; 64(3):292-303.
17.Comparative pharmacodynamics and
pharmacokinetics of oral direct thrombin and factor
Xa inhibitors in development. Clin Pharmacokinet.
2009; 48(1):1-22.
18. Effects of renal impairment on the
pharmacokinetics, pharmacodynamics and safety of
rivaroxaban, an oral, direct factor Xa inhibitor. Br J
Clin Pharmacol. 2010; 70(5):703-712.
19.Enoxaparin versus dabigatran or rivaroxaban for
thromboprophylaxis after hip or knee arthroplasty:
results of separate pooled analyses of phase III
multicenter randomized trials. Circ Cardiovasc Qual
Outcomes. 2010; 3(6):652-660.
20.Assessing the Safety Profiles of New Anticoagulants
for Major Orthopedic Surgery Thromboprophylaxis.
Clin Appl Thromb Hemost 2009; 15: 377-388
21.Validity of composite end points in clinical trials. BMJ
2005;330:594
22.Problems with use of composite end points in
cardiovascular trials: systematic review of
randomised controlled trials. BMJ 2007;334:786
23.Noninferiority trials. Curr Control Trials Cardiovasc
Med. 2000; 1(1): 19–21.
24.Per protocol analysis. BMJ 2010;340:c1825
25.MINISTERIO DE SALUD. Guía Clínica Endoprótesis
Total de Cadera en personas de 65 años y más con
Artrosis de Cadera con Limitación Funcional Severa.
1st Ed. Santiago: Minsal, 2005.
26.New anticoagulants.Circulation.
2010;121:1523-1532